{"text": ["U.S.", "FDA", "approves", "Amgen", "migraine", "drug,", "price", "set", "at", "$6900/yr"], "created_at": "2018-05-17 23:07:01"}
{"text": ["Roche", "Tecentriq", "Combo", "Achieves", "Longer", "Overall", "Survival", "Rate"], "created_at": "2018-05-17 16:32:46"}
{"text": ["Roche", "Tecentriq", "Combo", "Achieves", "Longer", "Overall", "Survival", "Rate"], "created_at": "2018-05-17 16:32:46"}
{"text": ["Exelixis", "Is", "Expected", "to", "Report", "a", "Robust", "Revenue", "Rise", "in", "2018"], "created_at": "2018-05-17 14:10:02"}
{"text": ["Teva\u2019s", "Fiscal", "Guidance:", "Confidence", "in", "Its", "Growth"], "created_at": "2018-05-17 11:32:29"}
{"text": ["Wired", "News", "\u2013", "Eli", "Lilly\u2019s", "Galcanezumab", "Met", "Primary", "Endpoint", "in", "Phase-3", "Study", "for", "Prevention", "of", "Episodic", "Cluster", "Headache"], "created_at": "2018-05-17 11:30:00"}
